GENE ONLINE|News &
Opinion
Blog

2021-06-10| In-DepthR&DTechnology

New IO Targets and Resistance Mechanisms of Immune Checkpoint-Based Therapies

by Isha Kapoor
Share To
At the ASCO 2021 virtual annual meeting, Dr. Antoni Ribas from UCLA, Dr. Patrick Alexander Ott from Dana Farber together with Dr. Kurt A. Schalper from Yale University teamed to discuss resistance mechanisms of checkpoint inhibitors, potential therapeutic combinations, neoantigen landscape, tumor mutational burden, and the role of tumor microenvironment in cancer immunotherapy.

Therapeutic resistance can be of two types, viz, primary resistance- wherein patients generally do not respond to therapy, and acquired resistance- where patients respond initially but still undergo disease progression.

GO Prime with only $1.49 now

LATEST
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-06-13
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
2024-06-12
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
2024-06-12
BIO Releases DEI Survey in Partnership with Korn Ferry
2024-06-11
Advancing Healthcare Accessibility and Sustainable Development
2024-06-11
New CRISPR Method Enables Gene Edits in Cockroaches and All Insects
2024-06-11
2024 Agri-Biotechnology Leadership Awards Announced at BIO in San Diego
2024-06-11
EVENT
Scroll to Top